CTLA4 and neoplasm: In a mouse glioma model, combination of oHSV with PD-1 and CTLA-4 blockade led to tumor regression in most mice and prevented tumor engraftment on tumor re-challenge in mice with initial tumor regression, suggesting that this combination therapy generated a lasting anti-tumor immune response (151).